Key takeaways

  • Proteomics International signed an exclusive three-year Australian pathology distribution agreement with Healius on 22 July 2026, covering PromarkerD, PromarkerEso and PromarkerEndo across more than 2,000 patient collection centres.
  • The Appendix 4C for the June 2026 quarter, lodged 27 July, reported A$128,000 of customer receipts, A$2.088 million of operating cash outflow, A$3.5 million of cash and an estimated 1.7 quarters of funding available.
  • The half-year accounts to December 2025 carried a disclosed material uncertainty over going concern, making the timing and pricing of any further capital raising a central question for holders.

Proteomics International Laboratories Limited (ASX:PIQ) has given small-cap investors a lesson in how quickly diagnostics sentiment turns. On 22 July 2026 the Perth company announced an exclusive national pathology distribution agreement with Healius, opening a route to more than 2,000 patient collection centres for its Promarker blood-test portfolio. Five days later it lodged an Appendix 4C showing A$3.5 million of cash and an estimated 1.7 quarters of funding available.

Both halves now sit before the market: the strongest distribution outcome the company has secured, and the tightest funding position it has reported.

Context matters more than the decimal place. On 3 July the company answered an ASX price query covering a move from a low of A$0.16 to a high of A$0.22, saying it was unaware of undisclosed information.

Latest announcement or development

The Appendix 4C for the three months to 30 June 2026 is the most recent price-sensitive filing. Receipts from customers were A$128,000 for the quarter and A$2.247 million for the year. Net operating cash outflow was A$2.088 million for the quarter and A$5.646 million for the twelve months, and cash closed at A$3.5 million, producing the 1.7-quarter funding estimate.

The company qualified that number, flagging about A$462,000 of non-recurring redundancy costs in the quarter and stating that, excluding those, funding extends beyond two quarters. It also expects an R&D tax incentive refund in the first half of FY27, having received A$2.687 million for FY26, and said financing discussions remain ongoing.

Recent financial and operational performance

The half-year accounts to 31 December 2025 capture the business before the restructure. Services revenue fell about 30 per cent to A$357,440, while net loss after tax widened to A$6.03 million from A$4.49 million. Directors disclosed a material uncertainty over going concern, stating that the group's ability to continue depends on raising additional funds.

April brought a structural response: a restructure removing roughly 25 per cent of positions, nine roles, for expected annualised savings above A$1 million. Founder Dr Richard Lipscombe retired, David Morris became chief executive and Tim Luscombe was appointed chief financial officer, in a stated shift from a research-driven organisation to a commercial diagnostics company.

Business model and principal assets

Two connected activities sit inside the company: a fee-for-service analytical laboratory in Perth, accredited to ISO 15189 and ISO 17025, and a proprietary diagnostics portfolio built on protein biomarker discovery. Nearly all revenue comes from the former; the investment case rests on the latter.

PromarkerD, a prognostic blood test predicting diabetes-related chronic kidney disease risk up to four years ahead, is the lead asset, with sensitivity of 76 to 85 per cent and specificity of 92 to 95 per cent cited in the strategic plan. PromarkerEso addresses oesophageal cancer risk and PromarkerEndo targets endometriosis diagnosis, while an oxidative-stress assay branded OxiDx is under strategic review.

Growth opportunities

The Healius agreement runs an initial three years with a mutual option for three more and covers all three Promarker tests in Australia. Healius handles specimen collection, referrer engagement and market access; Proteomics keeps testing, clinical reporting and regulatory compliance. Terms are confidential, and the company said revenue under it cannot be reliably estimated. A phased rollout is expected in FY27.

In the United States a CPT PLA billing code has been granted and Medicare set a reimbursement price of US$390.75 per test from 1 January 2026, though coverage still requires MolDX evaluation and a local coverage determination. The April strategic plan puts serviceable obtainable markets at about 20,000 annual tests in Australia and 390,000 in the United States for PromarkerD, with MBS listing via MSAC framed as a medium-term objective. A United States patent covering PromarkerEndo biomarkers was granted in July 2026, running to March 2041.

Balance sheet, funding and cash flow

This is the pressure point. At 31 December 2025 the group held A$7.67 million in cash against A$11.30 million of total assets and A$4.09 million of liabilities, leaving net assets of A$7.21 million. There are no bank borrowings, only modest lease liabilities. Cash fell to A$5.69 million at 31 March, with 2.2 quarters of funding estimated, and to A$3.5 million at 30 June, with 1.7.

The company raised A$12 million in June 2025 at A$0.37 per share, through a placement and an oversubscribed share purchase plan. About 165.4 million shares were quoted at mid-July 2026. Even allowing for the refund and lower costs, a funding decision looks necessary inside FY27.

Principal risks

Dilution is the immediate risk. Equity struck near recent trading levels would be far below the A$0.37 paid in the 2025 raise, and the going-concern uncertainty already disclosed leaves little slack.

Commercialisation risk follows. A distribution agreement is not demand: doctors must order the tests, and patients face private-pay pricing until reimbursement arrives. The MSAC pathway in Australia, and the MolDX and coverage determination processes in the United States, are lengthy and neither outcome is assured. Add a small, recently shrinking services revenue base, dependence on the annual R&D rebate, and execution risk after simultaneous changes of chief executive, chief financial officer and much of the workforce.